RESEARCH CHEMICAL ONLY — FOR IN VITRO / LABORATORY USE
This information is provided exclusively for educational and scientific reference purposes. This compound is NOT approved by the FDA or any regulatory agency for human or veterinary use. Administration into living organisms is FORBIDDEN BY LAW in many jurisdictions without appropriate licensure. All data presented here is sourced from peer-reviewed literature and is intended solely for in vitro (outside-the-body) research contexts.
This website does not provide medical advice, diagnosis, or treatment. Consult a licensed physician before making any health-related decisions.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a 31–amino-acid analog of the human incretin hormone GLP-1, acylated with a C18 fatty di-acid chain that binds albumin and extends its half-life to roughly one week, enabling once-weekly injection. Unlike the research peptides on this site, semaglutide is an FDA-approved medication marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management), developed by Novo Nordisk.
Mechanistically, it activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety through central appetite pathways. It is the most extensively studied compound in its class, and its dual-incretin successor is Tirzepatide. Because it is an approved drug backed by large randomized trials, the evidence base below is fundamentally stronger than that of unapproved research peptides.
Research Context
Evidence Level: Semaglutide is an FDA-approved drug supported by large, multi-year randomized controlled trials (RCTs) in humans. The findings below summarize published trial results. This page is educational and does not replace medical advice; dosing decisions for an approved drug belong with a prescribing clinician.
Overview
The semaglutide evidence base is exceptionally deep, spanning the SUSTAIN (diabetes), STEP (weight management), PIONEER (oral formulation), and SELECT (cardiovascular) programs — collectively tens of thousands of randomized participants published in NEJM, The Lancet, and JAMA. Research clusters around four themes: glycemic control in type 2 diabetes, weight reduction, cardiovascular outcomes, and formulation (injectable vs oral). Evidence maturity is high across all four, in contrast to the preclinical-only status of most peptides indexed on this site.
Type 2 Diabetes Glycemic Control (SUSTAIN)
The SUSTAIN program established semaglutide’s glycemic efficacy. Sorli et al. (2017) (SUSTAIN 1) showed that semaglutide monotherapy significantly reduced HbA1c and body weight versus placebo in drug-naïve type 2 diabetes. In a head-to-head trial, Pratley et al. (2018) (SUSTAIN 7) reported greater reductions in HbA1c and body weight than dulaglutide, positioning semaglutide as a best-in-class GLP-1 receptor agonist for glycemic control.
Weight Management (STEP)
The STEP program extended semaglutide to obesity without diabetes. The landmark trial Wilding et al. (2021) (STEP 1) reported a mean body-weight reduction of approximately 14.9% at 68 weeks with once-weekly 2.4 mg, versus 2.4% with placebo — the largest weight loss of any obesity pharmacotherapy at the time, as summarized in the review by Chao et al. (2023). This result underpinned the Wegovy approval for chronic weight management.
Cardiovascular Outcomes (SELECT, SUSTAIN-6)
Cardiovascular benefit distinguishes semaglutide from earlier weight-loss drugs. Marso et al. (2016) (SUSTAIN-6) first showed a significant reduction in major adverse cardiovascular events in high-risk type 2 diabetes (hazard ratio 0.74). Lincoff et al. (2023) (SELECT) then demonstrated a 20% reduction in cardiovascular events in patients with obesity and established cardiovascular disease without diabetes — a pivotal finding that reframed semaglutide as a cardiovascular-risk-reduction therapy, not merely a metabolic one.
Oral Formulation and Comparative Efficacy (PIONEER, head-to-head)
Semaglutide is also the first GLP-1 receptor agonist available orally. Husain et al. (2019) (PIONEER 6) established the cardiovascular safety of oral semaglutide in high-risk type 2 diabetes. In direct comparison with the dual agonist tirzepatide, Aronne et al. (2025) (SURMOUNT-5) and Frías et al. (2021) (SURPASS-2) reported greater weight loss and HbA1c reduction with tirzepatide, placing semaglutide as a highly effective but not maximal option within the incretin class.
Methodological Observations
The semaglutide literature is characterized by large, well-powered, placebo- and active-controlled RCTs with multi-year follow-up and hard clinical endpoints (HbA1c, body weight, cardiovascular events). This is a marked contrast to the small rodent studies typical of research peptides. Safety data are drawn from the same trial infrastructure; Smits and Van Raalte (2022) reviewed the comprehensive safety profile across the SUSTAIN and PIONEER programs.
Safety, GI Effects, and Limitations
- Gastrointestinal effects — Nausea, vomiting, diarrhea, and constipation are the most common adverse effects, driven by delayed gastric emptying, and are the leading cause of discontinuation.
- Boxed warning — A class thyroid C-cell tumor signal in rodents underlies a contraindication in personal/family history of medullary thyroid carcinoma or MEN 2.
- Lean-mass consideration — A portion of the weight lost is lean mass, a topic of ongoing study across the incretin class.
- Access and formulation — Compounded and research “reconstitution” semaglutide differs from the approved, quality-controlled product; potency and purity of non-pharmacy sources are not assured.
- Durability — Weight regain is common after discontinuation, indicating that benefit depends on continued therapy.
Reconstitution Mathematics
Some semaglutide is supplied as a lyophilized powder requiring reconstitution. The interactive calculator on this page handles all the arithmetic — but understanding the underlying formula is useful for verification:
Concentration (mg/mL) = Vial Size (mg) ÷ BAC Water Added (mL)
Dose Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL)
Syringe Units (IU) = Dose Volume (mL) × 100 [for U-100 insulin syringe]Common reconstitution examples:
| Vial Size | BAC Water | Concentration | 250 mcg dose |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 10 IU |
| 5 mg | 1 mL | 5.0 mg/mL | 5 IU |
| 10 mg | 2 mL | 5.0 mg/mL | 5 IU |
Use the interactive calculator on this page for any custom vial size, water volume, or dose.
Common Dosing Parameters
The following reflects the FDA-approved titration schedule for injectable semaglutide. Actual dosing must be directed by a prescribing clinician.
Approved semaglutide dosing uses a gradual titration to limit gastrointestinal side effects. IU values below assume a 5 mg vial reconstituted in 2 mL BAC water (2.5 mg/mL):
| Phase | Weekly Dose | Injection Volume | Syringe Units (IU) | Typical Duration |
|---|---|---|---|---|
| Initiation | 0.25 mg | 0.10 mL | 10 IU | Weeks 1–4 |
| Escalation | 0.5 mg | 0.20 mL | 20 IU | Weeks 5–8 |
| Escalation | 1.0 mg | 0.40 mL | 40 IU | Weeks 9–12 |
| Escalation | 1.7 mg | 0.68 mL | 68 IU | Weeks 13–16 |
| Maintenance | 2.4 mg | 0.96 mL | 96 IU | Ongoing (Wegovy) |
Key observations from the labeling and trials:
- The 0.25 mg starting dose is sub-therapeutic by design — it exists to build GI tolerance
- Diabetes maintenance (Ozempic) commonly targets 0.5–2.0 mg; weight management (Wegovy) targets 2.4 mg
- Titration pace should slow if GI effects are significant, per the approved labeling
- A 2.4 mg dose at 2.5 mg/mL nearly fills a 1 mL syringe — verify draw volume against syringe capacity
Stability & Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (dry powder) | −20 °C (freezer) | 24+ months |
| Reconstituted in BAC water | 2–8 °C (refrigerator) | Up to 28 days |
| Reconstituted, room temp | 20–25 °C | 48 hours maximum |
Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is the standard diluent for reconstitution because benzyl alcohol acts as a preservative. Approved pre-filled pens have their own manufacturer storage instructions, which differ from reconstituted powder.
Reconstitution procedure (for lyophilized product):
- Allow vial to reach room temperature (~15 minutes)
- Wipe septum with 70% isopropyl alcohol
- Draw desired BAC water volume into a sterile syringe
- Insert needle at a 45° angle and inject slowly along the vial wall — do not inject directly onto the lyophilized cake
- Gently swirl (do not shake or vortex) until fully dissolved
- Label vial with date, concentration, and store per table above
Frequently Asked Questions
How many units do I draw for 250 mcg of Semaglutide?
It depends on your reconstitution ratio. With a 5 mg vial in 2 mL BAC water (2.5 mg/mL concentration), a 250 mcg dose = 10 units on a U-100 insulin syringe. For a 0.5 mg dose it would be 20 units, and for the 2.4 mg maintenance dose, 96 units. Use the calculator above for your specific setup.
What is the difference between Semaglutide and Tirzepatide?
Semaglutide is a single-receptor GLP-1 agonist; Tirzepatide is a dual GIP/GLP-1 receptor agonist. In head-to-head trials (SURPASS-2, SURMOUNT-5), tirzepatide produced greater HbA1c and weight reductions, though both are highly effective. Use the multi-peptide mode if you need to model both.
Is Semaglutide the same as Ozempic and Wegovy?
Yes — semaglutide is the active ingredient. Ozempic and Rybelsus are approved for type 2 diabetes, while Wegovy is approved for weight management at the higher 2.4 mg maintenance dose. Rybelsus is the oral formulation; Ozempic and Wegovy are injectable.
How long does reconstituted Semaglutide last in the refrigerator?
Reconstituted in bacteriostatic water and stored at 2–8 °C, semaglutide is generally stable for up to 28 days. Approved pre-filled pens follow separate manufacturer dating. Always use a fresh alcohol swab before each draw, and discard cloudy or discolored solution.
Why does Semaglutide dosing start so low?
The 0.25 mg initiation dose is designed to build tolerance to gastrointestinal side effects (nausea, vomiting), not to treat — clinical efficacy comes at higher maintenance doses. This gradual titration is a defining feature of the approved labeling and was used across the SUSTAIN and STEP trials.
FOR RESEARCH PURPOSES ONLY. Not for human consumption. Not for veterinary use. Not a drug, food, or cosmetic.